{"id":"kariva","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Breakthrough bleeding"},{"rate":null,"effect":"Mood changes"}]},"_chembl":null,"_dailymed":{"setId":"7b11e11f-6977-4109-b9bd-a066e5d1278a","title":"KARIVA (DESOGESTREL/ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL) KIT [TEVA PHARMACEUTICALS USA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Kariva contains a progestin (desogestrel) and an estrogen (ethinyl estradiol) that work together to inhibit the luteinizing hormone (LH) surge required for ovulation. The progestin also thickens cervical mucus to impede sperm penetration and alters the endometrium to prevent implantation. This combination hormonal approach provides contraceptive efficacy through multiple mechanisms.","oneSentence":"Kariva is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and desogestrel.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:51.968Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception (prevention of pregnancy)"}]},"trialDetails":[{"nctId":"NCT07269327","phase":"PHASE1","title":"An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2025-11-24","conditions":"Fertility","enrollment":24},{"nctId":"NCT01005056","phase":"","title":"Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Contraception","enrollment":3838},{"nctId":"NCT00544882","phase":"PHASE3","title":"A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-10-31","conditions":"Healthy","enrollment":61},{"nctId":"NCT01252186","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women","status":"COMPLETED","sponsor":"Teva Women's Health","startDate":"2010-11","conditions":"Hemostasis, Oral Contraceptive","enrollment":265},{"nctId":"NCT01616225","phase":"PHASE2, PHASE3","title":"Growth Hormone in Poor Responders to IVF Trial","status":"TERMINATED","sponsor":"Pacific Centre for Reproductive Medicine","startDate":"2012-06","conditions":"Infertility","enrollment":60},{"nctId":"NCT00826839","phase":"PHASE4","title":"Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2009-01","conditions":"Infertility","enrollment":""},{"nctId":"NCT00612508","phase":"NA","title":"Hormonal Contraception and Vaginal Health","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2007-05","conditions":"Contraceptive Usage, Vaginal Epithelial Disruption","enrollment":14},{"nctId":"NCT01298128","phase":"NA","title":"NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment","status":"TERMINATED","sponsor":"University of Toronto","startDate":"2006-02","conditions":"Infertility, In-vitro Fertilization","enrollment":70},{"nctId":"NCT00185419","phase":"PHASE3","title":"A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-11","conditions":"Contraception","enrollment":842}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["desogestrel/ethinyl estradiol"],"phase":"marketed","status":"active","brandName":"Kariva®","genericName":"Kariva®","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Kariva is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and desogestrel. Used for Contraception (prevention of pregnancy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}